tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP), Milestone Pharmaceuticals (MIST) and Oric Pharmaceuticals (ORIC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cocrystal Pharma (COCPResearch Report), Milestone Pharmaceuticals (MISTResearch Report) and Oric Pharmaceuticals (ORICResearch Report).

Cocrystal Pharma (COCP)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cocrystal Pharma, with a price target of $4.00. The company’s shares closed last Wednesday at $0.39, close to its 52-week low of $0.37.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -45.1% and a 7.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Inovio Pharmaceuticals, and Aquestive Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cocrystal Pharma with a $4.50 average price target, implying a 1050.9% upside from current levels. In a report issued on May 12, Noble Financial also reiterated a Buy rating on the stock with a $5.00 price target.

See the top stocks recommended by analysts >>

Milestone Pharmaceuticals (MIST)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals, with a price target of $20.00. The company’s shares closed last Wednesday at $5.36.

According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -25.7% and a 24.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Precision BioSciences.

Currently, the analyst consensus on Milestone Pharmaceuticals is a Strong Buy with an average price target of $15.00, a 172.2% upside from current levels. In a report issued on May 13, Oppenheimer also reiterated a Buy rating on the stock with a $16.00 price target.

Oric Pharmaceuticals (ORIC)

H.C. Wainwright analyst Robert Burns reiterated a Hold rating on Oric Pharmaceuticals today. The company’s shares closed last Wednesday at $3.68, close to its 52-week low of $2.62.

According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.6% and a 17.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oric Pharmaceuticals with a $12.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COCP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More